sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3908> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_3908> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00530> ;
    a rdf:Statement ;
    rdfs:label "erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00530> bl:category bl:Drug .
}